Connect with us

Health

AbbVie Inc (NYSE:ABBV) Showcases Leadership In HCV With New MAVYRET™ Report To Be Introduced At The Liver Meeting® 2017

Published

on

AbbVie Inc (NYSE:ABBV) reported that it will showcase new data assessing MAVYRET™, its once-daily, ribavirin-free therapy for people with chronic hepatitis C virus infection across all key genotypes (GT1-6), at the yearly meeting of the AASLD.

Sixteen company scientific abstracts have been approved, including two oral presentations evaluating the application of MAVYRET in patients across genotypes with compensated cirrhosis and treatment-naïve subjects with genotype 3 HCV. These patients have historically had limited treatment alternatives. A third oral presentation assesses adherence to cure with MAVYRET in the clinical development plan. The Liver Meeting® 2017 is scheduled to take place from October 20 to October 24, 2017.

The details

Janet Hammond, M.D., Ph.D., the VP of Infectious Diseases Development at AbbVie, expressed that the company’s data presentations at The Liver Meeting 2017 reinforce their commitment to patients with hepatitis C. These data add to a strong collection of clinical study data to further improve scientific knowledge of MAVYRET’s efficacy and safety across a number of patient populations.

Researchers will also showcase data received from the MAVYRET clinical program assessing patients with metabolic, renal and cardiovascular conditions and data on HCV patient preferences.

Fred Poordad, M.D. expressed that on the back of AASLD’s newly introduced HCV treatment guidance, they are thrilled to witness additional data on MAVYRET across a broad range of subjects. The updated recommendations on accessible treatments, including the application of MAVYRET in the majority of people, serve as an additional source of data to assist physicians make treatment decisions.

In the last trading session, the stock price of AbbVie declined 0.35% to close the day at $91.42. The decline came at a share volume of 4.82 million compared to average share volume of 7.93 million. After the recent decline, the market cap of firm was seen at around $146 billion.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized4 days ago

Top 15 Essential Oils + Health Benefits

Top 15 Essential Oils + Health Benefits Each and every essential oil contains compounds with unique healing and therapeutic benefits....

Uncategorized4 days ago

Using Hemp Oil in Cooking

Hemp oil has many advocates. The oil from hemp seeds is rich in omega-3 and omega-6 essential fatty acids. This makes...

Uncategorized1 week ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health3 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business3 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business3 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business3 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP3 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP3 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP3 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

Advertisement
Advertisement
Advertisement